BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Engell CA, Pham VP, Holzman RS, Aberg JA. Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. ISRN Gastroenterol 2011;2011:405390. [PMID: 21991507 DOI: 10.5402/2011/405390] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Kang M, Hollabaugh K, Pham V, Koletar SL, Wu K, Smurzynski M, Aberg JA. Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort. J Acquir Immune Defic Syndr 2014;66:172-80. [PMID: 24694927 DOI: 10.1097/QAI.0000000000000149] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
2 Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, Flaherty J, Dinh P, Rossi S, Subramanian GM, Spivey J. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl. 2013;19:594-601. [PMID: 23447407 DOI: 10.1002/lt.23628] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 6.8] [Reference Citation Analysis]
3 Thai H, Lara J, Xu X, Kitrinos K, Gaggar A, Chan HLY, Xia GL, Ganova-Raeva L, Khudyakov Y. Complex genetic encoding of the hepatitis B virus on-drug persistence. Sci Rep 2020;10:15574. [PMID: 32968103 DOI: 10.1038/s41598-020-72467-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bihl F, Martinetti G, Wandeler G, Weber R, Ledergeber B, Calmy A, Battegay M, Cavassini M, Vernazza P, Caminada AP, Rickenbach M, Bernasconi E; Swiss HIV Cohort Study. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. BMC Gastroenterol 2015;15:79. [PMID: 26152237 DOI: 10.1186/s12876-015-0308-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
5 Utsumi T, Yano Y, Lusida MI, Nasronudin M, Juniastuti H, Hayashi Y. Detection of highly prevalent hepatitis B virus co-infection with HIV in Indonesia. Hepatol Res. 2013;43:1032-1039. [PMID: 23336705 DOI: 10.1111/hepr.12053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
6 Naing C, Poovorawan Y, Tong KS. Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis. BMC Infect Dis 2018;18:564. [PMID: 30428847 DOI: 10.1186/s12879-018-3506-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Nsubuga-Nyombi T, Sensalire S, Karamagi E, Aloyo J, Byabagambi J, Rahimzai M, Nabitaka LK, Calnan J. Multivariate analysis of covariates of adherence among HIV-positive mothers with low viral suppression. AIDS Res Ther 2018;15:9. [PMID: 29604955 DOI: 10.1186/s12981-018-0197-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, Kuzushita N, Mauss S, Núñez M, Nüesch R, Peters M, Reiberger T, Stephan C, Tan L, Gilson R. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS One 2013;8:e68152. [PMID: 23874527 DOI: 10.1371/journal.pone.0068152] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
9 Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, Lo Re V 3rd. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy. J Viral Hepat 2014;21:288-96. [PMID: 24597697 DOI: 10.1111/jvh.12142] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]